CD33 and acute myeloid leukemia: GO advantages were also associated with nucleophosmin 1 mutations (p ≤ 0.04), wild-type FMS-like tyrosine kinase 3 internal tandem duplication gene (p ≤ 0.03), age of <70 years (p < 0.05), <i>de novo</i> AML (p ≤ 0.017), and CD33(+) (p ≤ 0.021).